These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21808505)

  • 1. Zidovudine-induced myopathy: A study in Indian patients.
    Sagar A; Mohanty AP; Bahal A
    J Neurosci Rural Pract; 2010 Jul; 1(2):63-6. PubMed ID: 21808505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early features of zidovudine-associated myopathy: histopathological findings and clinical correlations.
    Cupler EJ; Danon MJ; Jay C; Hench K; Ropka M; Dalakas MC
    Acta Neuropathol; 1995; 90(1):1-6. PubMed ID: 7572071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscle disease, HIV and zidovudine: the spectrum of muscle disease in HIV-infected individuals treated with zidovudine.
    Manji H; Harrison MJ; Round JM; Jones DA; Connolly S; Fowler CJ; Williams I; Weller IV
    J Neurol; 1993 Sep; 240(8):479-88. PubMed ID: 8263554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of zidovudine on skeletal muscle mtDNA in HIV-1 infected patients with mild or no muscle dysfunction.
    Casademont J; Barrientos A; Grau JM; Pedrol E; Estivill X; Urbano-Márquez A; Nunes V
    Brain; 1996 Aug; 119 ( Pt 4)():1357-64. PubMed ID: 8813297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis in AZT myopathy.
    Chalmers AC; Greco CM; Miller RG
    Neurology; 1991 Aug; 41(8):1181-4. PubMed ID: 1714057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myopathies associated with human immunodeficiency virus and zidovudine: can their effects be distinguished?
    Simpson DM; Citak KA; Godfrey E; Godbold J; Wolfe DE
    Neurology; 1993 May; 43(5):971-6. PubMed ID: 8492955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human immunodeficiency virus type 1 infection and myopathy: clinical relevance of zidovudine therapy.
    Grau JM; Masanés F; Pedrol E; Casademont J; Fernández-Solá J; Urbano-Márquez A
    Ann Neurol; 1993 Aug; 34(2):206-11. PubMed ID: 8338345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skeletal muscle toxicity in HIV-1-infected patients treated with a raltegravir-containing antiretroviral therapy: a cohort study.
    Calza L; Danese I; Colangeli V; Vandi G; Manfredi R; Girometti N; Borderi M; Appolloni L; Puggioli C; Viale P
    AIDS Res Hum Retroviruses; 2014 Dec; 30(12):1162-9. PubMed ID: 25369244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of incidence of zidovudine induced anemia in Indian human immunodeficiency virus positive patients in comparison with stavudine based highly active antiretroviral therapy.
    Rajesh R; Vidyasagar S; Varma DM; Mohiuddin S; Noorunnisa
    Int J Risk Saf Med; 2011; 23(3):171-80. PubMed ID: 22020397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of the blood lactate:pyruvate ratio as a noninvasive test for the diagnosis of zidovudine myopathy.
    Chariot P; Monnet I; Mouchet M; Rohr M; Lefaucheur JP; Dubreuil-Lemaire ML; Chousterman M; Gherardi R
    Arthritis Rheum; 1994 Apr; 37(4):583-6. PubMed ID: 8147937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection.
    Chen SC; Barker SM; Mitchell DH; Stevens SM; O'Neill P; Cunningham AL
    Pathology; 1992 Apr; 24(2):109-11. PubMed ID: 1641255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myopathy in HIV infection: the role of zidovudine and the significance of tubuloreticular inclusions.
    Lane RJ; McLean KA; Moss J; Woodrow DF
    Neuropathol Appl Neurobiol; 1993 Oct; 19(5):406-13. PubMed ID: 8278024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome c oxidase reaction improves histopathological assessment of zidovudine myopathy.
    Chariot P; Monnet I; Gherardi R
    Ann Neurol; 1993 Oct; 34(4):561-5. PubMed ID: 8215243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS.
    Peters BS; Winer J; Landon DN; Stotter A; Pinching AJ
    Q J Med; 1993 Jan; 86(1):5-15. PubMed ID: 8438050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial myopathy caused by long-term zidovudine therapy.
    Dalakas MC; Illa I; Pezeshkpour GH; Laukaitis JP; Cohen B; Griffin JL
    N Engl J Med; 1990 Apr; 322(16):1098-105. PubMed ID: 2320079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuromuscular function in HIV infection: analysis of a placebo-controlled combination antiretroviral trial. AIDS Clinical Group 175/801 Study Team.
    Simpson DM; Katzenstein DA; Hughes MD; Hammer SM; Williamson DL; Jiang Q; Pi JT
    AIDS; 1998 Dec; 12(18):2425-32. PubMed ID: 9875580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study of acute muscle dysfunction with particular reference to dengue myopathy.
    Verma R; Holla VV; Kumar V; Jain A; Husain N; Malhotra KP; Garg RK; Malhotra HS; Sharma PK; Kumar N
    Ann Indian Acad Neurol; 2017; 20(1):13-22. PubMed ID: 28298837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Myopathy and zidovudine].
    Mateo O; Gato A; Ballesteros P; Benito L; Pontes MJ; Esquinas G
    Enferm Infecc Microbiol Clin; 1992 Oct; 10(8):474-6. PubMed ID: 1489776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colchicine-induced myopathy with normal creatine phosphokinase level in a renal transplant patient.
    Caglar K; Safali M; Yavuz I; Odabaşi Z; Yenicesu M; Vural A
    Nephron; 2002 Dec; 92(4):922-4. PubMed ID: 12399640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vesicular changes in the myopathies of AIDS. Ultrastructural observations and their relationship to zidovudine treatment.
    Panegyres PK; Papadimitriou JM; Hollingsworth PN; Armstrong JA; Kakulas BA
    J Neurol Neurosurg Psychiatry; 1990 Aug; 53(8):649-55. PubMed ID: 2170584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.